Alector ($ALEC): Analyst Targets Center on $3.60 With +99% Upside Potential (Check any stock’s price target on Tickeron.) The $3.60 central target is the arithmetic mean of four verified analyst price targets: $5.00 (H.C. Wainwright), $6.00 (BTIG), $2.00 (Morgan Stanley), and $1.50 (Mizuho). Based on Alector's October 2, 2026 close of $1.81, reaching $3.60 would require roughly a 99% advance — a very large move. The analyst range is extremely wide, from $1.50 to $6.00, reflecting deep disagreement after a late-2025 clinical setback and an October 2026 licensing deal. The strongest support is a new Genentech (Roche) agreement on the AL050 Parkinson's program, worth up to about $1.27 billion including an upfront payment. The biggest risks are ongoing clinical-stage losses, cash burn, and the history of trial-driven sell-offs. $ARCT $EDIT $CRBU $VYGR